Bet_Noire/iStock via Getty Images Johnson & Johnson ( NYSE: JNJ ) said a Phase 3 study of its drug Tremfya as a subcutaneous induction therapy was shown to be effective in treating adults with moderate-to-severe Crohn’s disease. The drugmaker said the study, called GRAVITI, met its co-primary endpoints of clinical remission and endoscopic response at Week 12. The company plans to submit the results to regulators.
Tremfya, an IL-23 inhibitor, is currently approved by the FDA for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. If approved for Crohn's, it would be the only full subcutaneous IL-23 therapy for both induction and maintenance for the condition, according to the company . J&J is also evaluating Tremfya as a subcutaneous induction therapy for ulcerative colitis.
More on Johnson & Johnson Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript) J&J's Talvey demonstrates robust long-term response in multiple myeloma Cancer victims seek court order to block J&J’s bankruptcy bid.
